- Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm
- Orexo Q1 2024 Interim Report
- Report from Orexo AB's annual general meeting, 26 April 2024
- Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US
- Orexo announces that the condition for early redemption of its existing bonds has been fulfilled
- Orexo publishes the Annual and Sustainability Report for 2023
- Correction: Notice of Annual General Meeting of Orexo
- Notice of Annual General Meeting of Orexo
- Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds
- Orexo contemplates issuance of senior secured callable floating rate social bonds and announces a conditional tender offer for its existing bonds
More ▼
Key statistics
On Wednesday, Orexo AB (ORX:STO) closed at 21.40, -8.15% below its 52-week high of 23.30, set on May 20, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 20.90 |
---|---|
High | 21.45 |
Low | 20.40 |
Bid | 21.40 |
Offer | 21.40 |
Previous close | 20.90 |
Average volume | 26.12k |
---|---|
Shares outstanding | 34.71m |
Free float | 27.47m |
P/E (TTM) | -- |
Market cap | 694.21m SEK |
EPS (TTM) | -2.13 SEK |
Data delayed at least 15 minutes, as of Jun 05 2024 17:00 BST.
More ▼